NZ265404A - Composition for treatment of hangover - Google Patents
Composition for treatment of hangoverInfo
- Publication number
- NZ265404A NZ265404A NZ265404A NZ26540494A NZ265404A NZ 265404 A NZ265404 A NZ 265404A NZ 265404 A NZ265404 A NZ 265404A NZ 26540494 A NZ26540494 A NZ 26540494A NZ 265404 A NZ265404 A NZ 265404A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- weight
- magnesium
- vitamin
- glucose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 27
- 206010019133 Hangover Diseases 0.000 title description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 239000008121 dextrose Substances 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 9
- 150000004682 monohydrates Chemical class 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 239000011787 zinc oxide Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 6
- 159000000001 potassium salts Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- RODZIAKMFCIGPL-UHFFFAOYSA-N P.I.I Chemical compound P.I.I RODZIAKMFCIGPL-UHFFFAOYSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number £65404
New Zealand No. 265404
International No, PCT/NZ94/00042
HO DRAtVIMfiS
J Priority Date(s): kfel.S.iSS'. I
CompSets Specification Filed:
Class:
E|P.I.I!».^J.$u^..0K|.3.S4>I^%yiv
Publication Date: 1 JIMM......
P.O. Journal No: .UfcR.'s?.,.
NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION
Title of Invention:
Monohydrate dextrose or glucose composition
Name, address and nationality of applicant(s) as in international application form:
HAMILTON, DONALD SINCLAIR, a New Zealand citizen of 1004 Colombo Street, Christchurch, New Zealand
265 ^ ^
TITLE: MONOHYDRATE DEXTROSE OR GLUCOSE COMPOSITION Background of the Invention
The present invention relates to a composition for the treatment of a "hangover" i.e. the after-effects of excessive consumption of ethyl alcohol by a human being.
Summary of the Invention
An object of the invention is the provision of a composition which can be taken as a single treatment (in one or more doses) to counteract a hangover.
The present invention provides a composition including:-a major proportion of mcnohydrate dextrose or glucose in combination with the following compounds:
(a) 0.5% - 2.4% by weight ascorbic acid;
(b) 0.0001% - 0.4% by weight of a non-toxic potassium salt;
(c) 0.0001% - 0.4% by weight of a non-toxic magnesium salt;
(d) 0.001% - 2.5% by weight vitamin B6;
(e) 0.0001% - 0.07% by weight of zinc oxide.
Detailed Description of the Invention
One of the known effects of alcohol in the human system is to lower the blood sugar, and this leads to an increase in
1
liver activity as the liver increases its normal rate of breaking down glycogen into blood sugar, to restore the optimum blood sugar level. continual or frequent such increase in liver activity can lead to cirrhosis of the liver.
The brain uses about 25% of available blood sugar, and so is particularly rapidly effected by a drop in blood sugar levels:- hence the symptoms of slurred speech, memory lapses, headaches, loss of co-ordination, blurred vision, personality changes, and so on commonly associated with alcohol consumption.
Monohydrate dextrose breaks down to glucose in the body, and thus both monohydrate dextrose and glucose are quickly and readily assimilated into the blood stream to boost the blood sugar level and help prevent liver damage and counteract brain disfunction.
The presence of alcohol in the system also is believed to increase the amount and frequency of urine passed, leading to a depletion of vitamin C, (ascorbic acid), magnesium and potassium in the system, and these losses need to be replaced to allow the system to resume functioning correctly. Examples of suitable magnesium and potassium salts are magnesium sulphate, magnesium oxide, and potassium phosphate.
It is believed that the presence in the composition of only minute traces of magnesium and potassium salts will be sufficient to stimulate the release of adequate supplies of these salts from the body's own stores. An alternative explanation of the effectiveness of the compound of the
WO 94/27449 PCT/NZ94/00042
present invention is that the body requires only minute traces of the magnesium and potassium salts to make up the deficiencies caused by alcohol. However, a higher proportion of magnesium and potassium salts may be advantageous. One or 5 more potassium salts and one or more magnesium salts may be used.
Also, it is believed that the magnesium and potassium salts and vitamin C are much more readily and easily absorbed into the system if taken into the system with monohydrate 10 dextrose or glucose:- the monohydrate dextrose or glucose effectively coats said other constituents and prevents them from being destroyed by stomach acids, and also speeds their circulation around the system.
Zinc oxide assists the pancreas with the production of 15 insulin, and hence facilitates the absorption of glucose into the blood. Zinc oxide also is known to be effective in detoxifying the system i.e. combatting the after-effects of alcohol.
It is believed that the presence of vitamin B6 in the 20 composition considerably increases the rate of activity of the composition and thus gives more rapid relief to a user. It appears that vitamin B6 and magnesium salts are synergistic i.e. the presence of one increases the effectiveness of the other, and thus reduces the amount of each needed in the 25 composition to achieve the desired effect.
Thus, the constituents of the composition act to raise the user's blood sugar level and replenish lost vitamin C,
3
magnesium and potassium, and also interact with each other to mutually increase their effectiveness and to speed their assimilation into the system.
Optionally, the composition also may contain one or more of the following:
(a) 0.5% - 2% by weight powdered citric acid, to improve the palatability of the composition?
(b) 0.5% - 5% by weight powdered calcium phosphate, to replenish calcium losses.
A preferred embodiment of the present composition comprises:.
(a)
2.4% ascorbic acid;
(b)
1.1% citric acid;
(c)
0.4% vitamin B6;
(d)
0.1% magnesium sulphate;
(e)
0.1% potassium phosphate;
(f)
0.1% magnesium oxide;
(g)
0.03% zinc oxide;
(h)
95.77% monohydrate dextrose;
(all % by weight).
The composition is in the form of a powder, and is taken dissolved in water or in tablet form. It has been found that the composition is more effective if the user lies on the right side after taking the composition, because this allows the composition to pass more quickly though the duodenum into the intestine, for absorption into the system.
Alternatively, the composition may be prepared in liquid
4
Claims (6)
1. A composition including:- a major proportion of monohydrate dextrose or glucose in combination with the following compounds: (a) 0.5% - 2.4% by weight ascorbic acid; (b) 0.0001% - 0.4% by weight of a non-toxic potassium salt; (c) 0.0001% - 0.4% by weight of a non-toxic magnesium salt; (d) 0.001% - 2.5% by weight vitamin B6; (e) 0.0001% - 0.07% by weight of zinc oxide.
2. The composition as claimed in Claim 1, further including 0.5% - 2% by weight of citric acid.
3. The composition as claimed in Claim 1 or Claim 2, further including 0.5% - 5% by weight of calcium phosphate.
4. A composition comprising (a) 2.4% ascorbic acid; (b) 1.1% citric acid; (c) 0.4% vitamin B6; (d) 0.1% magnesium sulphate; (e) 0.1% potassium phosphate; (f) 0.1% magnesium oxide; (g) 0.03% zinc oxide; (h) 95.77% monohydrate dextrose; (all % by weight).
5. The composition as claimed in any preceding cla PCT/NZ94/00042 265 4 0 4 wherein said composition is in the form of a powder.
6. The composition as claimed in any preceding claim, wherein said composition is in the form of a liquid. WO 94/27449 7
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ265404A NZ265404A (en) | 1993-05-26 | 1994-05-10 | Composition for treatment of hangover |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ24770193 | 1993-05-26 | ||
| NZ265404A NZ265404A (en) | 1993-05-26 | 1994-05-10 | Composition for treatment of hangover |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ265404A true NZ265404A (en) | 1996-06-25 |
Family
ID=26651190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ265404A NZ265404A (en) | 1993-05-26 | 1994-05-10 | Composition for treatment of hangover |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ265404A (en) |
-
1994
- 1994-05-10 NZ NZ265404A patent/NZ265404A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5597585A (en) | Vitamin/mineral composition | |
| AU619029B2 (en) | Compositions and methods for achieving improved physiological response to excercise | |
| US5089477A (en) | Compositions and methods for achieving improved physiological response to exercise | |
| CN101557807A (en) | Nutritional supplement composition for treatment of ocular diseases | |
| GB9517443D0 (en) | Increasing creatine and glycogen concentration in muscle | |
| CA2162877C (en) | Monohydrate dextrose or glucose composition | |
| LU87348A1 (en) | MAGNESIUM-BASED MINERAL ADDITIVE FOR NUTRIENTS, FOODSTUFFS AND MEDICINAL PRODUCTS | |
| KR0163583B1 (en) | Treatment of hypertension by oral administration of potassium bicarbonate | |
| KR20000067771A (en) | Method for maintaining oxidative metabolism attendant upon exercise and food for sport | |
| DE68903147T2 (en) | COMPOSITIONS AND METHOD FOR OBTAINING AN IMPROVED PHYSIOLOGICAL REACTION IN LIFE EXERCISES. | |
| US5639482A (en) | Composition for control and prevention of diabetic retinopathy | |
| JP2533709B2 (en) | Physical strength enhancer | |
| NZ265404A (en) | Composition for treatment of hangover | |
| DE68910126T2 (en) | FOOD COMPOSITION. | |
| JP2002265365A (en) | Neutrophil function inhibitor | |
| US20090062231A1 (en) | Appetite Suppressant Composition and Method of Appetite Suppression | |
| AU651824B2 (en) | Pharmaceutical composition | |
| EP2408317B1 (en) | Dietary supplement | |
| JP3241173B2 (en) | Bath additive | |
| KR20120110955A (en) | A functional beverage composition comprising taurine, inositol, vitamin c, vitamin b complex, potassium iodide as main ingredients | |
| JP2007314560A (en) | Agents that sustain oxidative metabolism that accompanies exercise | |
| JPH0414082B2 (en) | ||
| JP2002080376A (en) | Biologically active agent and medicine | |
| JPH0640901A (en) | Agent for suppressing toxicity of acetaldehyde | |
| US4474801A (en) | α-Amino-γ-butyrolactones for treating alcohol dependence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |